The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The Times share tip is handy in giving whoever is selling down IHC, plenty of liquidity to sell into.
Already 342,000 shares traded. Hopefully once the seller is out, IHC can move on upwards, just needs a couple of decent contract wins.
From today's Times:
Inspiration Healthcare’s share price chart would bring doctors running if it flashed up on monitors in the hospitals where its intensive care products are used. From 68p in 2020, the firm, which specialises in neonatal medical machines and aids, saw its stock more than double in the following 12 months before crashing back down to 84p over distribution issues in China last November and halving again to 45p now.
It’s either an ideal time to snap up a bargain in this Crawley-based medtech distributor — or it’s a dud that was overvalued in the Covid years, when its ventilators saw high demand from the NHS. Which is correct?
Inspiration was founded in 2003, and listed on Aim in 2015 via a reverse takeover of Inditherm, which specialises in technology that warms up very sick patients. Today, Inspiration’s key products include the all-in-one SLE6000 ventilator, non-invasive ventilators for babies and cerebral function monitoring systems; the firm sells its own UK-made products in 75 countries, generating 60 per cent of profits from overseas. Its neonatal market specialism is seeing growing demand: more than 15 million babies are born prematurely every year, but that figure is rising worldwide. The neonatal intensive care market is worth $6.8 billion and set to approach $10 billion by 2027, according to analysts ResearchandMarkets.com.
Yet Inspiration’s own trends have not reflected that opportunity. Results for the year to February were muted, with revenues almost flat at £41 million and underlying earnings falling from £6 million a year earlier to £4 million. Chief executive Neil Campbell said the firm had shown “resilience”, a barrel-scraper of a verdict.
There are reasons for cheer: Inspiration invested in a new manufacturing and technology centre in Croydon, increasing both its capacity and capability. It has reliable, high-quality customers, and revenues picked up in the fourth quarter of its last financial year, and amounted to almost £2 million cash in the first two months of its 2024 year. Its policy of investing about 9per cent of sales into R&D should gradually pay off.
Seb Jantet, analyst at house broker Liberum, is realistic: “the recent track record and poor cash generation warrant some caution,” he says, but names a punchy 100p target price because “Inspiration’s core offering is sound and … we expect the discount to peers to close.”
The price to earnings ratio is 9.6 for 2023, down from over 12 last year. Inspiration is a dicey investment, but its medical technology’s time has come: buy.
Were we supposed to get a trading update today? The rns about the investor day mentioned it would include a trading update, would they would not also have to also rns the update? Unless I've misunderstood the rns..
This share must be at the bottom now.....
You get everywhere mag lol. I don't care what they say, I quite like your posts!!!
This one looks good,
doing some more dd later
have plenty of orders
Just bought back in. Always liked this company. Gla.
Yeah I’m a master of the art form of understatement. A better description would be an absolute shocker of a RNS. I await the results with trepidation
Bit of an understatement that Herring!
Not the most positive of updates. Hopefully the market won’t pan it today
Further to my post yesterday and having spoken with IHC the reason for the confusion was due to having a new high tech phone system being installed at the time of my call and the receptionist also being new to the position.
The receptionist was very polite and helpful and having spoken with a member of the sales team today I feel very confident that IHC are experts in their field and will deliver great results for Genedrive.
I just rang to see if I could speak to someone about the Genedrive MT-RNR1 kit and I wasn't that impressed tbh.
Seemed very chaotic and unsure of what I was talking about.
The Genedrive MT-RNR1 kit is advertised on the IHC website so I had expected the receptionist to know what it was.
Perhaps I caught them at a bad time but I hope for GDR's sake these guys are capable of delivering results.
Simon still positive.
https://www.investorschronicle.co.uk/ideas/2022/10/04/a-medtech-winner-in-neonatal-intensive-care/
GLA
Announcement includes the 2nd mention of £0.6m Japanese order for delivery this financial year yet 1st mention of two rather larger orders (each around £1.3m) to Iraq & Egypt respectively. Are those to be delivered in 2nd half of this year or were they delivered in whole or part the 1st half ?
Yes not what we wanted to SEE!
But have modern new production facilties and stock
Poor HI results. Revenue slightly down at £20.5m (LY HI 20.9m) but margins lower at 45.1% (LY 52.5%), Operating profit £1.1m (LY £2.6m) and cash at £3.3m (LY £8.6m). Cash down due to expansion costs and building inventory for H2.
Had been a fan and holder here for several years but sold this morning, before share price collapsed 15%.
May come good in H2, but too many risks with wider economy at present.
RNS wasn't as bad as the market has reacted.... actually fairly positive based on the current economic situation. Still in profit and paying a dividend.
Anyone have an idea as to where the bottom is here?
Down 10% in one day for no apparent reason, until the MMs dropped in a large sell (272k at 82p from around lunchtime) later in the day. Whoever did this must be desperate for cash. Share was around 95-98p prior to sell.
Anyone sensible would have sold in blocks and got a decent price.
Still happy to take advantage and have added more at 85.5p
IHC at Mello2022 investor days on 25/26th May - actively presenting both days and around for chats to investors
The Hyland news article states that revenue might drop by 15% next year. The RNS states that modelling of a 15% drop has been undertaken to verify that borrowing facilities are adequate. The two things are very different. Perhaps the drop in share price today reflects the news article rather than the RNS.